| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
RIFAMYCIN B
ID: ALA307649
Max Phase: Preclinical
Molecular Formula: C45H53IN2O13
Molecular Weight: 956.82
Molecule Type: Small molecule
Associated Items:
Representations
Synonyms (1): Rifamycin B
Synonyms from Alternative Forms(1):
Canonical SMILES: COC1/C=C/OC2(C)Oc3c(C)c(O)c4c(O)c(cc(OCC(=O)Nc5ccc(I)cc5)c4c3C2=O)NC(=O)/C(C)=C\C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C
Standard InChI: InChI=1S/C45H53IN2O13/c1-21-11-10-12-22(2)44(56)48-30-19-32(58-20-33(50)47-29-15-13-28(46)14-16-29)34-35(40(30)54)39(53)26(6)42-36(34)43(55)45(8,61-42)59-18-17-31(57-9)23(3)41(60-27(7)49)25(5)38(52)24(4)37(21)51/h10-19,21,23-25,31,37-38,41,51-54H,20H2,1-9H3,(H,47,50)(H,48,56)/b11-10+,18-17+,22-12-
Standard InChI Key: BHDJFLBHWKKNQU-FMAVLDMNSA-N
Associated Targets(Human)
ABCC1 Tchem Multidrug resistance-associated protein 1 (2587 Activities)
Associated Targets(non-human)
Escherichia coli (133304 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Staphylococcus aureus (210822 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Enterococcus faecalis (29875 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Streptococcus pyogenes (16140 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Bacillus subtilis (32866 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mdr1a Multidrug resistance protein 1a (106 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 956.82 | Molecular Weight (Monoisotopic): 956.2592 | AlogP: 6.67 | #Rotatable Bonds: 6 |
| Polar Surface Area: 219.41 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 6 |
| #RO5 Violations: 4 | HBA (Lipinski): 15 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 4 |
| CX Acidic pKa: 7.09 | CX Basic pKa: | CX LogP: 6.16 | CX LogD: 5.67 |
| Aromatic Rings: 3 | Heavy Atoms: 61 | QED Weighted: 0.09 | Np Likeness Score: 1.40 |
References
| 1. Bacchi A, Pelizzi G, Nebuloni M, Ferrari P.. (1998) Comprehensive study on structure-activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin O., 41 (13): [PMID:9632365] [10.1021/jm970791o] |
| 2. Lukovits I, Lopata A.. (1980) Decomposition of pharmacological activity indices into mutually independent components using principal component analysis., 23 (4): [PMID:7381845] [10.1021/jm00178a018] |
| 3. Courtois A, Payen L, Vernhet L, de Vries EG, Guillouzo A, Fardel O.. (1999) Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells., 139 (1): [PMID:10408915] [10.1016/s0304-3835(99)00024-5] |
| 4. Fardel O, Lecureur V, Loyer P, Guillouzo A.. (1995) Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells., 49 (1): [PMID:7763306] [10.1016/0006-2952(95)00045-2] |
Source
Source(2):